Although mutations of either IDH1 or IDH2 in gliomas are heterozygous, they have an impact on drug resistance as both IDH1 and IDH2 form homodimers to exert their catalytic function and mutant homodimers and heterodimers are inactive [89]. Here, IDH2 is linked to glioma.